How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

The Respond Study Group; Bastian Neesgaard; Amanda Mocroft; Lauren Greenberg; Jakob Friis Larsen; Ole Kirk; Daria Podlekareva; Dorthe Raben; Lars Peters; Alain Volny-Anne; Jens Lundgren; Lene Ryom

doi:10.3390/microorganisms8081164

How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

The Respond Study Group, Bastian Neesgaard, Amanda Mocroft, Lauren Greenberg, Jakob Friis Larsen, Ole Kirk, Daria Podlekareva, Dorthe Raben, Lars Peters, Alain Volny-Anne, Jens Lundgren, Lene Ryom

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

25 Citationer (Scopus)

41 Downloads (Pure)

Abstract

BACKGROUND: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.

METHODS: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.

RESULTS: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.

CONCLUSION: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

Originalsprog	Engelsk
Artikelnummer	1164
Tidsskrift	Microorganisms
Vol/bind	8
Antal sider	16
ISSN	2076-2607
DOI	https://doi.org/10.3390/microorganisms8081164
Status	Udgivet - 2020

Adgang til dokumentet

10.3390/microorganisms8081164Licens: CC BY

microorganisms-08-01164-v2Forlagets udgivne version, 1,06 MBLicens: CC BY

Citationsformater

@article{f9f67066dd714cef868ac1c6e16829e2,

title = "How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium",

abstract = "BACKGROUND: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.METHODS: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.RESULTS: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-na{\"i}ve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.CONCLUSION: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.",

author = "{The Respond Study Group} and Bastian Neesgaard and Amanda Mocroft and Lauren Greenberg and Larsen, {Jakob Friis} and Ole Kirk and Daria Podlekareva and Dorthe Raben and Lars Peters and Alain Volny-Anne and Jens Lundgren and Lene Ryom",

year = "2020",

doi = "10.3390/microorganisms8081164",

language = "English",

volume = "8",

journal = "Microorganisms",

issn = "2076-2607",

publisher = "M D P I AG",

}

TY - JOUR

T1 - How to RESPOND to Modern Challenges for People Living with HIV

T2 - A Profile for a New Cohort Consortium

AU - The Respond Study Group

AU - Neesgaard, Bastian

AU - Mocroft, Amanda

AU - Greenberg, Lauren

AU - Larsen, Jakob Friis

AU - Kirk, Ole

AU - Podlekareva, Daria

AU - Raben, Dorthe

AU - Peters, Lars

AU - Volny-Anne, Alain

AU - Lundgren, Jens

AU - Ryom, Lene

PY - 2020

Y1 - 2020

N2 - BACKGROUND: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.METHODS: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.RESULTS: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.CONCLUSION: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

AB - BACKGROUND: the International Cohort Consortium of Infectious Disease (RESPOND) is a collaboration dedicated to research on HIV and other infectious diseases.METHODS: RESPOND is a flexible organization, with several independent substudies operating under one shared governance. HIV-related variables, including full antiretroviral therapy (ART) history, are collected annually for all participants and merged with substudy specific data into a shared data pool. Incident clinical events are reported using standardized forms. Prospective follow-up started 1/10/17 (enrolment) with retrospective data collected back to 01/01/12.RESULTS: Overall, 17 cohorts from Europe and Australia provided data on 26,258 people living with HIV (PLWH). The majority (43.3%) of the population were white, with men-sex-with-men accounting for 43.3% of the risk for HIV acquisition. The median age was 48 years (IQR 40-56) and 5.2% and 25.5% were known to be co-infected with hepatitis B or C. While 5.3% were ART-naïve, the median duration on ART was 10.1 years (4.8-17.6), with 89.5% having a VL <200 copies/mL and the median CD4 count being 621 cells/µL (438-830). Malignancies (n = 361) and cardiovascular disease (n = 168) were the predominant reported clinical events.CONCLUSION: RESPOND's large, diverse study population and standardized clinical endpoints puts the consortium in a unique position to respond to the diverse modern challenges for PLWH.

U2 - 10.3390/microorganisms8081164

DO - 10.3390/microorganisms8081164

M3 - Journal article

C2 - 32752044

SN - 2076-2607

VL - 8

JO - Microorganisms

JF - Microorganisms

M1 - 1164

ER -